Monday, June 12, 2023 9:35:20 AM
https://www.accesswire.com/760298/Ra-Medicals-Electrophysiology-Division-Announces-First-Hospital-to-Complete-100-Procedures-Using-the-VIVO-System
FORT MILL, SC / ACCESSWIRE / June 12, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has had its first customer, Heart Hospital of New Mexico at Lovelace Medical Center, complete 100 ventricular ablation procedures with the assistance of VIVO, a non-invasive 3D imaging system that identifies the earliest electrical activation of a ventricular arrhythmia.
"This is a significant milestone for Catheter Precision", said David Jenkins, interim CEO. "We continue to believe that physicians and hospitals will find value using VIVO and to see a hospital use it this much in a relatively short period of time demonstrates that the benefits of VIVO are being recognized and that our utilization strategies are working."
VIVO is used to assist physicians in physicians in pre-procedure planning for ventricular ablations. When used in advance of the procedure, VIVO can provide additional information to the physician about the patient's heart to streamline what are often long and complicated procedures lasting 4-5 hours.
Dr Sean Mazer, MD, clinical Electrophysiologist at the Heart Hospital of New Mexico and president of the New Mexico Heart Institute/Lovelace Medical Group says, "We have implemented VIVO in all of our PVC ablations. It has helped speed up and improve the workflow for our most difficult procedures. It has also improved the chances of successful ablation for the patients. Some of these arrhythmias were not treatable without VIVO."
Catheter Precision recently built out a direct sales team in early 2023 to expand upon the successful, but limited launch and to expand its footprint across the United States.
Recent RMED News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/03/2024 09:02:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/03/2024 09:01:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2024 08:20:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2023 08:16:48 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 08:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:19:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2023 08:16:05 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/20/2023 08:26:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/14/2023 08:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 08:15:42 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM